Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Medical Microbiology and Immmunology

• Publication date

  2012-11-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00430-012-0278-6PMID 23143437
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• IL-1β and TGFβ2 synergistically induce endothelial to mesenchymal transition in an NFκB-dependent manner.

  2013cited by this paper
• Mycobacterium tuberculosis: immune evasion, latency and reactivation.

  2012cited by this paper
• Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.

  2012cited by this paper
• Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China

  2012cited by this paper
• Lipid Body–Phagosome Interaction in Macrophages during Infectious Diseases: Host Defense or Pathogen Survival Strategy?

  2012cited by this paper
• Potential of Host Markers Produced by Infection Phase-Dependent Antigen-Stimulated Cells for the Diagnosis of Tuberculosis in a Highly Endemic Area

  2012cited by this paper
• Mycobacterium tuberculosis: success through dormancy.

  2012influential reference
• Confronting multidrug-resistant tuberculosis.

  2012cited by this paper
• Tuberculosis: cost of illness in Germany

  2012cited by this paper
• Totally drug-resistant tuberculosis in India.

  2012cited by this paper
• Reply to Alffenaar

  2012cited by this paper
• How Mycobacterium tuberculosis goes to sleep: the dormancy survival regulator DosR a decade later.

  2012cited by this paper
• Surgical treatment of drug-resistant tuberculosis.

  2012cited by this paper
• Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting

  2012cited by this paper
• The immunological footprint of Mycobacterium tuberculosis T-cell epitope recognition.

  2012cited by this paper
• Targeting Persisters for Tuberculosis Control

  2012influential reference
• Scaling up interventions to achieve global tuberculosis control: progress and new developments.

  2012cited by this paper
• The chemotherapy of tuberculosis: past, present and future [State of the art].

  2012cited by this paper
• Pulmonary resection for extensively drug resistant tuberculosis in Kwazulu-Natal, South Africa.

  2012cited by this paper
• Antiretroviral Therapy for Prevention of Tuberculosis in Adults with HIV: A Systematic Review and Meta-Analysis

  2012cited by this paper
• Fluorescein diacetate vital staining allows earlier diagnosis of rifampicin-resistant tuberculosis.

  2012cited by this paper
• Extrapulmonary locations of mycobacterium tuberculosis DNA during latent infection.

  2012cited by this paper
• Vitamin D Inhibits Human Immunodeficiency Virus Type 1 and Mycobacterium tuberculosis Infection in Macrophages through the Induction of Autophagy

  2012cited by this paper
• Delamanid for multidrug-resistant pulmonary tuberculosis.

  2012cited by this paper
• National survey of drug-resistant tuberculosis in China.

  2012cited by this paper
• Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of Tuberculosis

  2012cited by this paper
• Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance

  2012cited by this paper
• Tuberculosis, drug resistance, and the history of modern medicine.

  2012cited by this paper
• Adjunct immunotherapies for tuberculosis.

  2012cited by this paper
• Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go?

  2012cited by this paper
• Inside or outside the phagosome? The controversy of the intracellular localization of Mycobacterium tuberculosis.

  2012cited by this paper
• New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future.

  2012cited by this paper
• Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients

  2012cited by this paper
• Revisiting the role of the granuloma in tuberculosis

  2012cited by this paper
• Limited-Sampling Strategies for Therapeutic Drug Monitoring of Moxifloxacin in Patients With Tuberculosis

  2011cited by this paper
• Autophagy in the immune response to tuberculosis: clinical perspectives

  2011cited by this paper
• Innate Immune Recognition of Mycobacterium tuberculosis

  2011cited by this paper
• Interferon Gamma Activated Macrophages Kill Mycobacteria by Nitric Oxide Induced Apoptosis

  2011cited by this paper
• Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk

  2011cited by this paper
• Treatment of tuberculosis: update 2010

  2011cited by this paper
• The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices

  2011cited by this paper
• Tuberculosis vaccines: beyond bacille Calmette–Guérin

  2011cited by this paper
• Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB

  2011cited by this paper
• Characterization and Transcriptome Analysis of Mycobacterium tuberculosis Persisters

  2011cited by this paper
• Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience

  2011cited by this paper
• Mycobacterium vaccae as Adjuvant Therapy to Anti-Tuberculosis Chemotherapy in Never-Treated Tuberculosis Patients: A Meta-Analysis

  2011cited by this paper
• The secret trumps, impelling the pathogenicity of tubercle bacilli.

  2011cited by this paper
• Prospects for a new, safer and more effective TB vaccine.

  2011cited by this paper
• Immunology in tuberculosis: challenges in monitoring of disease activity and identifying correlates of protection.

  2011cited by this paper
• Nutritional status and vitamin D3 during antimicrobial treatment.

  2011cited by this paper
• Vitamin D Is Required for IFN-γ–Mediated Antimicrobial Activity of Human Macrophages

  2011cited by this paper
• Susceptibility of Clinical Mycobacterium tuberculosis Isolates to a Potentially Less Toxic Derivate of Linezolid, PNU-100480

  2011cited by this paper
• A multistage tuberculosis vaccine that confers efficient protection before and after exposure

  2011cited by this paper
• Immune protection against tuberculosis--when is immunotherapy preferable to vaccination?

  2011cited by this paper
• Successful immunotherapy of canine flea allergy with injected Actinomycetales preparations.

  2011cited by this paper
• Revisiting the Natural History of Tuberculosis

  2010cited by this paper
• Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity

  2010cited by this paper
• Phase 2 Trial of V-5 Immunitor (V5) in Patients with Chronic Hepatitis C Co-infected with HIV and Mycobacterium Tuberculosis

  2010cited by this paper
• New vaccines for tuberculosis.

  2010cited by this paper
• Mathematical Modeling of Tuberculosis Bacillary Counts and Cellular Populations in the Organs of Infected Mice

  2010cited by this paper
• Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model.

  2010cited by this paper
• MDR tuberculosis--critical steps for prevention and control.

  2010cited by this paper
• Future vaccination strategies against tuberculosis: thinking outside the box.

  2010cited by this paper
• Prevention of tuberculosis in Bacille Calmette–Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine

  2010cited by this paper
• Novel tuberculosis vaccination strategies based on understanding the immune response

  2010cited by this paper
• Comparison of the Pharmacokinetics of Two Dosage Regimens of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis Patients

  2010cited by this paper
• Update on research and development pipeline: tuberculosis vaccines.

  2010cited by this paper
• Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000–2004

  2010cited by this paper
• The immunology of tuberculosis: From bench to bedside

  2010cited by this paper
• Tuberculous Granuloma Induction via Interaction of a Bacterial Secreted Protein with Host Epithelium

  2010cited by this paper
• T Cell Reactivity against Mycolyl Transferase Antigen 85 of M. tuberculosis in HIV-TB Coinfected Subjects and in AIDS Patients Suffering from Tuberculosis and Nontuberculous Mycobacterial Infections

  2010cited by this paper
• Treatment of tuberculosis and optimal dosing schedules

  2010cited by this paper
• The origin of fibroblasts and mechanism of cardiac fibrosis

  2010cited by this paper
• Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI.

  2010cited by this paper
• Limited Sampling Strategies for Therapeutic Drug Monitoring of Linezolid in Patients With Multidrug-Resistant Tuberculosis

  2010cited by this paper
• Immunogenicity of Novel DosR Regulon-Encoded Candidate Antigens of Mycobacterium tuberculosis in Three High-Burden Populations in Africa

  2009cited by this paper
• Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis.

  2009cited by this paper
• The spectrum of latent tuberculosis: rethinking the biology and intervention strategies

  2009cited by this paper
• Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.

  2009cited by this paper
• Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.

  2009cited by this paper
• The common mycobacterial antigens and their importance in the treatment of disease.

  2009cited by this paper
• Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung.

  2008cited by this paper
• Foamy Macrophages from Tuberculous Patients' Granulomas Constitute a Nutrient-Rich Reservoir for M. tuberculosis Persistence

  2008cited by this paper
• Bacterial Growth and Cell Division: a Mycobacterial Perspective

  2008cited by this paper
• Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death.

  2008cited by this paper
• Mycobacterial persistence requires the utilization of host cholesterol

  2008cited by this paper
• Cytological and Transcript Analyses Reveal Fat and Lazy Persister-Like Bacilli in Tuberculous Sputum

  2008cited by this paper
• Human macrophage host defense against Mycobacterium tuberculosis.

  2008cited by this paper
• Immunological Outcomes of New Tuberculosis Vaccine Trials: WHO Panel Recommendations

  2008cited by this paper
• First tuberculosis cases in Italy resistant to all tested drugs.

  2007cited by this paper
• How a different look at latency can help to develop novel diagnostics and vaccines against tuberculosis

  2007cited by this paper
• Mycobacterium tuberculosis invasion of macrophages: linking bacterial gene expression to environmental cues.

  2007cited by this paper
• Improved outcome of Trypanosoma cruzi infection in rats following treatment in early life with suspensions of heat-killed environmental Actinomycetales.

  2007cited by this paper
• Expression profiling of host pathogen interactions: how Mycobacterium tuberculosis and the macrophage adapt to one another.

  2006cited by this paper
• Tuberculosis and granuloma formation in patients receiving anti-TNF therapy.

  2006cited by this paper
• Early and rapid microscopy-based diagnosis of true treatment failure and MDR-TB.

  2006cited by this paper
• RUTI: a new chance to shorten the treatment of latent tuberculosis infection.

  2006cited by this paper
• Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.

  2006cited by this paper
• Is Adipose Tissue a Place for Mycobacterium tuberculosis Persistence?

  2006cited by this paper
• Intragranulomatous necrosis in lungs of mice infected by aerosol with Mycobacterium tuberculosis is related to bacterial load rather than to any one cytokine or T cell type.

  2006cited by this paper

• TAK1 phosphorylation mediates macozinone (PBTZ169) induced innate immune activation against tuberculosis

  2025cites this paper
• Conquering the tuberculosis Superbug: Innovative approaches for biofilm disruption and antibiotic resistance mitigation

  2025cites this paper
• Enhanced Immune Responses Against Mycobacterium tuberculosis Through Heat-Killed BCG with Squalene-in-water Emulsion Adjuvant

  2024cites this paper
• Drug-resistant strains of Mycobacterium tuberculosis: cell envelope profiles and interactions with the host

  2023cites this paper
• Targeted Anti-Biofilm Therapy: Dissecting Targets in the Biofilm Life Cycle

  2022cites this paper
• Design and Synthesis of Quinazolinone-Triazole Hybrids as Potent Anti-Tubercular Agents.

  2022cites this paper
• A score years' update in the synthesis and biological evaluation of medicinally important 2-pyridones.

  2022cites this paper
• Synthesis, antitubercular, antimicrobial activities and molecular docking study of quinoline bearing dihydropyrimidines.

  2021cites this paper
• Oxazolyl-pyrimidines as antibacterial and antitubercular agents: synthesis, biological evaluation, in-silico ADMET and molecular docking study

  2021cites this paper
• Synthesis of 6‐[4‐(4‐Propoxyphenyl)piperazin‐1‐yl]‐9H‐purine Derivatives as Antimycobacterial and Antifungal Agents: In Vitro Evaluation and In Silico Study

  2020cites this paper
• Induction of autophagy through CLEC4E in combination with TLR4: an innovative strategy to restrict the survival of Mycobacterium tuberculosis

  2020cites this paper
• Approaches in scaling up schistosomiasis intervention towards transmission elimination in Africa: leveraging from the Chinese experience and lessons.

  2020cites this paper
• Curdlan Limits Mycobacterium tuberculosis Survival Through STAT-1 Regulated Nitric Oxide Production

  2019cites this paper
• Novel vaccination strategies and approaches against human tuberculosis

  2019cites this paper
• RUTI Vaccination Enhances Inhibition of Mycobacterial Growth ex vivo and Induces a Shift of Monocyte Phenotype in Mice

  2019cites this paper
• Historical BCG vaccination combined with drug treatment enhances inhibition of mycobacterial growth ex vivo in human peripheral blood cells

  2019cites this paper
• Accelerating development of therapeutic tuberculosis vaccines using an ex vivo immune assay platform

  2019cites this paper
• The current status of bacillus Calmette‐Guérin vaccine protective efficacy

  2019cites this paper
• Enhancement of immune response against Mycobacterium tuberculosis HspX antigen by incorporation of combined molecular adjuvant (CASAC).

  2019cites this paper
• Characterisation of immune responses to mycobacterial infections in a murine model of type 2 diabetes

  2018cites this paper
• Synthesis, biological evaluation, and molecular docking study of pyridine clubbed 1,3,4-oxadiazoles as potential antituberculars

  2018cites this paper
• New Governance Models for Discoveries of Vaccine Science

  2018cites this paper
• Clinical management of drug resistant Mycobacterium tuberculosis strains: Pathogen-targeted versus host-directed treatment approaches.

  2018cites this paper
• Development of tuberculosis vaccines in clinical trials: Current status

  2018cites this paper
• Introduction

  2018cites this paper
• The current status, challenges, and future developments of new tuberculosis vaccines

  2018influential citation
• A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis

  2018cites this paper
• In vivo electroporation of a codon-optimized BERopt DNA vaccine protects mice from pathogenic Mycobacterium tuberculosis aerosol challenge.

  2018cites this paper
• Vacinação contra a tuberculose : será o fim do BCG na Europa?

  2017cites this paper
• Synthesis and biological evaluation of novel 1,2,3-triazole derivatives as anti-tubercular agents.

  2017cites this paper
• Design, synthesis and in vitro anti-tuberculosis activity of benzo[6,7]cyclohepta[1,2-b]pyridine-1,2,3-triazole derivatives.

  2017cites this paper
• Knowledge of tuberculosis and vaccine trial preparedness in Lima, Peru.

  2017cites this paper
• Cost of care for hospitalized patients with pulmonary mycobacterial diseases in the United States.

  2016cites this paper
• Synthesis and molecular docking studies of a new series of bipyrazol-yl-thiazol-ylidene-hydrazinecarbothioamide derivatives as potential antitubercular agents

  2016cites this paper
• Infergen Stimulated Macrophages Restrict Mycobacterium tuberculosis Growth by Autophagy and Release of Nitric Oxide

  2016cites this paper
• Drug-resistant TB: deadly, costly and in need of a vaccine

  2016cites this paper
• PET/CT imaging of Mycobacterium tuberculosis infection

  2016cites this paper
• Mycobacterium tuberculosis infection and vaccine development.

  2016cites this paper
• Preparation, biological evaluation and molecular docking study of imidazolyl dihydropyrimidines as potential Mycobacterium tuberculosis dihydrofolate reductase inhibitors.

  2016cites this paper
• Global Efforts in the Development of Vaccines for Tuberculosis: Requirements for Improved Vaccines Against Mycobacterium tuberculosis

  2016cites this paper
• Research progress in the field of immunotherapeutic vaccination in human TB and the way ahead.

  2016cites this paper
• Revisiting co-trimoxazole for the treatment of tuberculosis

  2016cites this paper
• Totally drug‐resistant tuberculosis and adjunct therapies

  2015cites this paper
• Linezolid in multidrug-resistant tuberculosis

  2015cites this paper
• Synthesis and evaluation of novel fluorinated pyrazolo-1,2,3-triazole hybrids as antimycobacterial agents.

  2015cites this paper
• Design, Synthesis, and Biological Evaluation of 1,4‐dihydropyridine Derivatives as Potent Antitubercular Agents

  2015cites this paper
• Synthesis of New Mannich Products Bearing Quinoline Nucleous Using Reusable Ionic Liquid and Antitubercular Evaluation

  2015cites this paper
• Current Concepts of commonly used Vaccines

  2015cites this paper
• Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs.

  2014cites this paper
• Rational design, synthesis and antitubercular evaluation of novel 2-(trifluoromethyl)phenothiazine-[1,2,3]triazole hybrids.

  2014cites this paper
• Immunotherapeutic efficacy of recombinant Mycobacterium smegmatis expressing Ag85B–ESAT6 fusion protein against persistent tuberculosis infection in mice

  2014cites this paper
• 4,5-Dihydro-1H-pyrazolo[3,4-d]pyrimidine containing phenothiazines as antitubercular agents.

  2014cites this paper
• Rational design and synthesis of novel dibenzo[b,d]furan-1,2,3-triazole conjugates as potent inhibitors of Mycobacterium tuberculosis.

  2014cites this paper
• Vaccination against infectious diseases: What is promising?

  2014cites this paper
• Novel vaccination strategies against tuberculosis.

  2014cites this paper
• Recent advances towards tuberculosis control: vaccines and biomarkers

  2014cites this paper
• Catalytic regioselective synthesis of pyrazole based pyrido[2,3-d]pyrimidine-diones and their biological evaluation.

  2014cites this paper
• Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons.

  2014cites this paper
• Immunotherapy of tuberculosis with Mycobacterium leprae Hsp65 as a DNA vaccine triggers cross-reactive antibodies against mammalian Hsp60 but not pathological autoimmunity

  2014cites this paper
• High-throughput identification and dendritic cell-based functional validation of MHC class I-restricted Mycobacterium tuberculosis epitopes

  2014cites this paper
• Therapeutic vaccines for tuberculosis--a systematic review.

  2014cites this paper
• Studies on molecular properties prediction, antitubercular and antimicrobial activities of novel quinoline based pyrimidine motifs.

  2014cites this paper
• Host-directed therapy of tuberculosis: what is in it for microRNA?

  2014cites this paper
• Tuberculosis vaccine development at a divide

  2014cites this paper
• Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review.

  2014cites this paper
• Randomized, placebo-controlled phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7)

  2013cites this paper
• Design, synthesis and antitubercular evaluation of novel 2-substituted-3H-benzofuro benzofurans via palladium-copper catalysed Sonagashira coupling reaction.

  2013cites this paper
• The Lancet Infectious Diseases Commission Antibiotic resistance—the need for global solutions

  2013cites this paper
• Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis

  2013cites this paper
• Antibiotic resistance-the need for global solutions.

  2013cites this paper
• Drug resistente tuberculose: oude en nieuwe inzichten rond een wereldwijde epidemie

  2013cites this paper
• Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7).

  2013cites this paper
• Evaluation of the overall IFN-γ and IL-17 pro-inflammatory responses after DNA therapy of tuberculosis

  2013cites this paper